Claims (1)
ISTEMLER . Oral yoldan inhalasyon seklinde uygulanmak üzere antikolinerjik grubundaki uygun etken madde ve/veya farmasötik olarak kabul edilebilir türevlerinin monoterapi olarak tek basina kullanildigi ve/veya bu etken maddenin diger uygun aktif ajan/lar ile kombine tedavi olarak kullanildigi farinasötik bilesim/lerin hazirlanmasi. . Istem l,deki gibi farmasötik bilesim/ler olup özelligi; antikolinerjikler grubunda yer alan etken maddenin ipratropium, oksitropium, tiotropium, umeklidinyum ve/veya farmasötik olarak kabul edilebilir türevleri arasindan seçilmesidir. . Istem 2,deki gibi farmasötik bilesim/ler olup özelligi; antikolinerjikler grubunda yer alan etken maddenin tercihen umeklidinyum bromür olmasidir. . Istem 1,deki gibi farmasötik bilesim/ler olup özelligi; oral yoldan inhalasyon seklinde uygulama için hazirlanan farmasötik bilesim/lerin; kuru toz içeren kapsül, kuru toz içeren bIISter, çok dozlu blister seklindeki disk gibi bir dozaj sekilleri arasindan seçilmesidir. . Istem 3,deki gibi farmasötik bilesim/ler olup özelligi; oral yoldan inhalasyon seklinde uygulama için hazirlanan farmasötik bilesim/lerin kuru toz içeren blISter formunda olmasidir. . Istem 1'deki gibi farmasötik bilesim/ler olup özelligi; inhalasyon yoluyla uygulamanin ölçülü doz inhalatör, kuru toz inhalatör veya nebülizasyon gibi inhalasyon yoluyla uygulama çesitleri arasindan seçilmesidir. . Istem 57deki gibi farmasötik bilesim/ler olup özelligi; inhalasyon yoluyla uygulamanin tercihen kuru toz inhalatör olmasidir. . Yukaridaki istemlerden herhangi birine göre farmasötik bilesim/ler olup özelligi; uygun etken madde/ler ve/veya farmasötik olarak kabul edilebilir türevlerini içeren farmasötik bilesimdeki umeklidinyum ve/veya farmasötik olarak kabul edilebilir türevleri miktarinin 0.1-800mcg olmasidir. Kronik ve akut bronsit, Kronik Obstruktif Akciger Hastaligi (KOAH), amfizem gibi akciger hastaliklarinin profilaktik ve/veya semptomatik ve/veya terapötik tedavisinde endike-bir ilacin üretiminde istem 1,e göre sunulan bir farmasötik bilesimin kullanimi.REQUESTS . Preparation of pharmaceutical composition(s) for oral administration as inhalation, in which the appropriate active ingredient in the anticholinergic group and/or pharmaceutically acceptable derivatives are used alone as monotherapy and/or this active ingredient is used as a combined treatment with other suitable active agent/s. . It is a pharmaceutical composition/s as in claim 1 and its feature is; The active ingredient in the group of anticholinergics is selected among ipratropium, oxitropium, tiotropium, umeclidinium and/or pharmaceutically acceptable derivatives. . It is a pharmaceutical composition/s as in Claim 2 and its feature is; The active ingredient in the group of anticholinergics is preferably umeclidinium bromide. . It is a pharmaceutical composition/s as in Claim 1 and its feature is; pharmaceutical composition(s) prepared for oral inhalation administration; It is the choice of dosage forms such as capsule containing dry powder, biscuits containing dry powder, disc in the form of multi-dose blister. . It is a pharmaceutical composition/s as in claim 3, and its feature is; is that the pharmaceutical composition(s) prepared for oral administration as inhalation is in the form of blisters containing dry powder. . It is a pharmaceutical composition/s as in Claim 1 and its feature is; It is the selection of administration by inhalation among the types of administration by inhalation such as metered dose inhaler, dry powder inhaler or nebulization. . It is a pharmaceutical composition/s as in Claim 57 and its feature is; by inhalation is preferably a dry powder inhaler. . It is a pharmaceutical composition/s according to any of the above claims and its feature is; The amount of umeclidinium and/or pharmaceutically acceptable derivatives in the pharmaceutical composition containing the appropriate active ingredient/s and/or pharmaceutically acceptable derivatives is 0.1-800mcg. Use of a pharmaceutical composition according to claim 1 in the manufacture of a medicament indicated for the prophylactic and/or symptomatic and/or therapeutic treatment of lung diseases such as chronic and acute bronchitis, Chronic Obstructive Pulmonary Disease (COPD), emphysema.